Combined EGFR and MEK inhibition prevents the emergence of drug resistance in EGFR mutant non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Tricker, Erin M. [1 ]
Xu, Chunxiao [1 ]
Ercan, Dalia [1 ]
Ogino, Atsuko [1 ]
Wong, Kwok-kin [1 ]
Janne, Pasi [1 ]
机构：
[1] DFCI, Boston, MA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1832
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1832
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
    Tricker, Erin M.
    Xu, Chunxiao
    Uddin, Sharmeen
    Capelletti, Marzia
    Ercan, Dalia
    Ogino, Atsuko
    Pratilas, Christine A.
    Rosen, Neal
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Jaenne, Pasi A.
    [J]. CANCER DISCOVERY, 2015, 5 (09) : 960 - 971
  • [2] Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer
    Lantermann, Alexandra B.
    Chen, Dongshu
    McCutcheon, Kaitlin
    Hoffman, Greg
    Frias, Elizabeth
    Ruddy, David
    Rakiec, Daniel
    Korn, Joshua
    McAllister, Gregory
    Stegmeier, Frank
    Meyer, Matthew J.
    Sharma, Sreenath V.
    [J]. CANCER RESEARCH, 2015, 75 (22) : 4937 - 4948
  • [3] Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
    Tan, Aaron C.
    Teh, Yi Lin
    Lai, Gillianne G. Y.
    Tan, Daniel S. W.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 431 - 435
  • [4] A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
    Li, Liu
    Qu, Jingjing
    Heng, Jianfu
    Zhou, Chunhua
    Xiong, Yi
    Yang, Haiyan
    Jiang, Wenjuan
    Zeng, Liang
    Zhu, Songlin
    Zhang, Yongchang
    Tan, Jiarong
    Hou, Ting
    Lizaso, Analyn
    Chen, Zhiqiu
    Hu, Chengping
    Deng, Pengbo
    Yang, Nong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
    Tan, A.
    Chua, K. P.
    Teng, Y.
    Takano, A.
    Alvarez, J.
    Nahar, R.
    Rohatgi, N.
    Lai, G.
    Aung, Z.
    Yeong, J.
    Lim, K. H. T.
    Naeini, M.
    Kassam, I.
    Jain, A.
    Tan, W.
    Gogna, A.
    Too, C. W.
    Kanesvaran, R.
    Ng, Q. S.
    Ang, M.
    Rajasekaran, T.
    Devanand, A.
    Phua, G. C.
    Tan, B. S.
    Lee, Y. Y.
    Wang, L.
    Teo, A.
    Khng, A.
    Lim, M. J.
    Suteja, L.
    Toh, C. K.
    Lim, W.
    Iyer, N. G.
    Tam, W. L.
    Tan, E.
    Zhai, W.
    Hillmer, A.
    Skanderup, A.
    Tan, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S184 - S184
  • [6] Efficacy of Focal Adhesion Kinase (FAK) Inhibition in RAS Mutant and EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
    Zhang, Hao
    Shao Huanjie
    Chen, Hongbin
    Golubovskaya, Vita
    Cance, William
    Adjei, Alex
    Dy, Grace
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S594 - S594
  • [7] EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer
    Syrigos, K.
    Tsagouli, S.
    Gkiozos, I.
    Paraskeva, M.
    Kotteas, I.
    Tsimpoukis, S.
    Zontanos, M.
    Grapsa, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S903 - S903
  • [8] ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS
    Janjigian, Y. Y.
    Smit, E. F.
    Horn, L.
    Groen, H. J. M.
    Camidge, D. R.
    Gettinger, S.
    Fu, Y.
    Denis, L. J.
    Miller, V.
    Pao, W.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 401 - 401
  • [9] Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer
    Ko, J.
    Kim, Y.
    Park, M.
    Cui, Z.
    Ahn, M.
    Park, K.
    [J]. EJC SUPPLEMENTS, 2008, 6 (09): : 29 - 30
  • [10] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
12345